Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/INTERPACE BIOSCIENCES INC/ 8-K

Current Report · Items 8.01, 9.01 · 8-K

INTERPACE BIOSCIENCES INC

Other Events

Item 8.01 Other Events. On December 3, 2025, Interpace Biosciences, Inc. issued a press release announcing that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners prior to the facility’s maturity date. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

Filed Dec 3, 2025Accepted Dec 3, 2025, 11:05 AM ESTCIK 1054102Accession 0001493152-25-025960
View company →Permanent SEC source ↗
Share

Company context

We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features. We develop and commercialize genomic tests that can personalize medicine to help improve patient diagnosis and management. Due to the decision of CMS to cease reimbursement coverage of our PancraGEN® test for assessing the risk of pancreatic cyst progression to cancer on April 24, 2025 which resulted in specimens for first-line fluid chemistry and PancraGEN® testing not being accepted by the Company after May 2, 2025, we are currently concentrating our efforts on our molecular diagnostic tests for thyroid cancer, ThyGeNEXT® and ThyraMIR®v2.

Current securities

IDXGOTC · EQUITY · Current
Historical securities (2)
IDGGWOTC · WARRANT · Historical · closed Jun 21, 2022IDXGDOTC · EQUITY · Historical · closed Sep 22, 2026

Recent company filings

  1. S-1 filingSep 25, 2026
  2. S-8 filingSep 17, 2026
  3. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD DisclosureAug 27, 2026
  4. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 26, 2026
  5. Submission of Matters to a Vote of Security HoldersAug 21, 2026

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On December 3, 2025, Interpace Biosciences, Inc. issued a press release announcing that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners prior to the facility’s maturity date. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners PARSIPPANY, NJ, Dec 3, 2025 (GLOBE NEWSWIRE) - Interpace Biosciences, Inc. (OTCID : IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners (“BroadOak”) prior to the facility’s maturity date. The repayment satisfies the Company’s obligations under the Loan and Security Agreement originally entered into on October 29, 2021, with BroadOak Fund V, L.P. By retiring this debt early, Interpace eliminates related interest expenses, providing increased operational flexibility to support future growth. “The early repayment of the BroadOak facility is a significant milestone for Interpace and a testament to our robust financial performance and disciplined capital management,” said Chris McCarthy, Chief Financial Officer. “Over the past several years, BroadOak has been a valuable partner, supporting our strategic turnaround and transition to profitability. With this debt retired, we have strengthened our balance sheet, positioning us to focus our full resources on driving c…

Open exhibit ↗